Persisting gender differences and attenuating age differences in cardiovascular drug use for prevention and treatment of coronary heart disease, 1998-2010

European Heart Journal

Volumn 34, Issue 41, 2013, Pages 3198-3205

  Koopman, Carla ^a,c   Vaartjes, Ilonca ^a   Heintjes, Edith M ^b   Spiering, Wilko ^a   Dis, Inekevan ^c   Herings, Ron M C ^b   Bots, Michiel L ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b PHARMO INSTITUTE FOR DRUG OUTCOMES RESEARCH   (Netherlands)

^c Dutch Heart Foundation   (Netherlands)

Author keywords

Age; Cardiovascular drugs; Coronary heart disease; Gender; Prevention; Trends

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIENOPYRIDINE DERIVATIVE;

ACUTE CORONARY SYNDROME; ADULT; AGE; AGED; ARTICLE; DRUG USE; FEMALE; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; PRIMARY PREVENTION; PRIORITY JOURNAL; SECONDARY PREVENTION; SEX DIFFERENCE;

AGE; CARDIOVASCULAR DRUGS; CORONARY HEART DISEASE; GENDER; PREVENTION; TRENDS;

ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; CARDIOVASCULAR AGENTS; CORONARY DISEASE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEALTHCARE DISPARITIES; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; NETHERLANDS; PRIMARY PREVENTION; SECONDARY PREVENTION; SEX DISTRIBUTION;

EID: 84890065847     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/eht368     Document Type: Article

References (31)

1. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-952.
2. WHO. The top 10 causes of death. Factsheet no. 310, updated June 2011. (http://www.who.int/mediacentre/factsheets/fs310/en/index.html) (6 September 2013).
3. National Institute for Health and Clinical Excellence. Clinical guideline 48 MI: Secondary prevention in primary and secondary care for patients following a myocardial infarction. London: NICE, 2007. www.nice.org.uk/CG48 (6 September 2013).
4. van Dis I, Geleijnse JM, Verschuren WM, Kromhout D. Cardiovascular risk management of hypertension and hypercholesterolaemia in the Netherlands: From unifactorial to multifactorial approach. Neth Heart J 2012;20:320-325.
5. Dutch College of General Practitioners (NHG). M84: NHG-Standaard Cardiovasculair risicomanagement, 2011. http://www.nhg.org/standaarden/ samenvatting/cardiovasculair-risicomanagement (6 September 2013).
6. The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012;33:1635-1701. doi:10.1093/eurheartj/ehs092.
7. Lahoz C, Mantilla T, Taboada M, Soler B, Tranche S, Lopez-Rodriguez I, Monteiro B, Martin-Jadraque R, Sanchez-Zamoran MA, Mostaza JM. Gender differences in evidence-based pharmacological therapy for patients with stable coronary heart disease. Int J Cardiol 2009;133:336-340.
8. Lee HY, Cooke CE, Robertson TA. Use of secondary prevention drug therapy in patients with acute coronary syndrome after hospital discharge. J Manag Care Pharm 2008;14:271-280.
9. Setoguchi S, Glynn RJ, Avorn J, Levin R, Winkelmayer WC. Ten-year trends of cardiovascular drug use after myocardial infarction among community-dwelling persons. or 65 years of age. Am J Cardiol 2007;100:1061-1067.
10. Simpson CR, Hannaford PC, Williams D. Evidence for inequalities in the management of coronary heart disease in Scotland. Heart 2005;91:630-634.
11. Tjia J, Briesacher B, Xie D, Fu J, Goldberg RJ. Disparities in combination drug therapy use in older adults with coronary heart disease: A cross-sectional time-series in a nationally representative US sample. Drugs Aging 2010;27:149-158.
12. Sheppard JP, Singh S, Fletcher K, McManus RJ, Mant J. Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: Cross sectional study. BMJ 2012;345:e4535.
13. Herings R, Pedersen L. Pharmacy-based medical record linkage systems. In: Strom B, Kimmel SE, Hennessy S (eds), Pharmacoepidemiology. 5th ed. John Wiley & Sons, Ltd; 2012, p270-286.
14. Mantel-Teeuwisse AK, Klungel OH, Verschuren WM, Porsius A, de Boer A. Comparison of different methods to estimate prevalence of drug use by using pharmacy records. J Clin Epidemiol 2001;54:1181-1186.
15. Lau HS, de Boer A, Beuning KS, Porsius A. Validation of pharmacy records in drug exposure assessment. J Clin Epidemiol 1997;50:619-625.
16. Collier DJ, Poulter NR, Dahlof B, Sever PS,Wedel H, Buch J, Caulfield MJ. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. J Hypertens 2011;29:592-599.
17. Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, Cobbe SM, Ford I, Gaw A, Hyland M, Jukema JW, Kamper AM, Macfarlane PW, Meinders AE, Norrie J, Packard CJ, Perry IJ, Stott DJ, Sweeney BJ, Twomey C,Westendorp RG. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002;360:1623-1630.
18. Fox KA, Steg PG, Eagle KA, Goodman SG, Anderson FA Jr, Granger CB, Flather MD, Budaj A, Quill A, Gore JM. Decline in rates of death and heart failure in acute coronary syndromes, 1999-2006. JAMA 2007;297:1892-1900.
19. Perers E, Caidahl K, Herlitz J, Karlson BW, Karlsson T, Hartford M. Treatment and short-term outcome in women and men with acute coronary syndromes. Int J Cardiol 2005;103:120-127.
20. Hirakawa Y, Masuda Y, Kuzuya M, Iguchi A, Kimata T, Uemura K. Age differences in the delivery of cardiac management to women versus men with acute myocardial infarction: An evaluation of the TAMIS-II data. Int Heart J 2006;47:209-217.
21. The Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012;33:2569-2619. doi:10.1093/eurheartj/ehs215.
22. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2011;32: 2999-3054. doi:10.1093/eurheartj/ehr236.
23. DeWilde S, Carey IM, Richards N, Whincup PH, Cook DG. Trends in secondary prevention of ischaemic heart disease in the UK 1994 2005: Use of individual and combination treatment. Heart 2008;94:83-88.
24. Filippi A, D'Ambrosio G, Giustini SE, Pecchioli S, Mazzaglia G, Cricelli C. Pharmacological treatment after acute myocardial infarction from 2001 to 2006: A survey in Italian primary care. J Cardiovasc Med (Hagerstown) 2009;10:714-718.
25. Breekveldt-Postma NS, Penning-van Beest FJ, Siiskonen SJ, Falvey H, Vincze G, Klungel OH, Herings RM. The effect of discontinuation of antihypertensives on the risk of acute myocardial infarction and stroke. Curr Med Res Opin 2008;24: 121-127.
26. DeWilde S, Carey IM, Bremner SA, Richards N, Hilton SR, Cook DG. Evolution of statin prescribing 1994-2001: A case of agism but not of sexism Heart 2003;89: 417-421.
27. Ramsay SE, Morris RW, Papacosta O, Lennon LT, Thomas MC, Whincup PH. Secondary prevention of coronary heart disease in older British men: Extent of inequalities before and after implementation of the National Service Framework. J Public Health (Oxf) 2005;27:338-343.
28. Murphy NF, Simpson CR, MacIntyre K, McAlister FA, Chalmers J, McMurray JJ. Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: Age, sex and socioeconomic disparities: A population-based study. Heart 2006;92:1047-1054.
29. Macchia A, Romero M, D'Ettorre A, Mariani J, Tognoni G. Temporal trends of the gaps in post-myocardial infarction secondary prevention strategies of co-morbid and elderly populations vs. younger counterparts: An analysis of three successive cohorts between 2003 and 2008. Eur Heart J 2012;33:515-522.
30. West SL, Strom BL, Freundlich B, Normand E, Koch G, Savitz DA. Completeness of prescription recording in outpatient medical records from a health maintenance organization. J Clin Epidemiol 1994;47:165-171.
31. KildemoesHW,Hendriksen C, Andersen M. Drug utilization according to reason for prescribing: A pharmacoepidemiologic method based on an indication hierarchy. Pharmacoepidemiol Drug Saf 2012;21:1027-1035.